332 related articles for article (PubMed ID: 25897811)
61. New approaches to chikungunya virus vaccine development.
Garcia A; Diego L; Judith B
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(1):31-7. PubMed ID: 25706528
[TBL] [Abstract][Full Text] [Related]
62. Development of Neutralization Assay Using an eGFP Chikungunya Virus.
Deng CL; Liu SQ; Zhou DG; Xu LL; Li XD; Zhang PT; Li PH; Ye HQ; Wei HP; Yuan ZM; Qin CF; Zhang B
Viruses; 2016 Jun; 8(7):. PubMed ID: 27367716
[TBL] [Abstract][Full Text] [Related]
63. Current Strategies for Inhibition of Chikungunya Infection.
Subudhi BB; Chattopadhyay S; Mishra P; Kumar A
Viruses; 2018 May; 10(5):. PubMed ID: 29751486
[TBL] [Abstract][Full Text] [Related]
64. Chikungunya virus drug discovery: still a long way to go?
Pérez-Pérez MJ; Delang L; Ng LFP; Priego EM
Expert Opin Drug Discov; 2019 Sep; 14(9):855-866. PubMed ID: 31177861
[No Abstract] [Full Text] [Related]
65. An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling.
Dora EG; Rossi SL; Weaver SC; Tucker SN; Mateo R
Vaccine; 2019 May; 37(24):3146-3150. PubMed ID: 31047675
[TBL] [Abstract][Full Text] [Related]
66. Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development.
Rezza G; Weaver SC
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006919. PubMed ID: 30653504
[TBL] [Abstract][Full Text] [Related]
67. Targeting Chikungunya virus by computational approaches: from viral biology to the development of therapeutic strategies.
Rabelo VW; Paixão ICNP; Abreu PA
Expert Opin Ther Targets; 2020 Jan; 24(1):63-78. PubMed ID: 31914351
[No Abstract] [Full Text] [Related]
68. Evolution and immunopathology of chikungunya virus informs therapeutic development.
Henderson Sousa F; Ghaisani Komarudin A; Findlay-Greene F; Bowolaksono A; Sasmono RT; Stevens C; Barlow PG
Dis Model Mech; 2023 Apr; 16(4):. PubMed ID: 37014125
[TBL] [Abstract][Full Text] [Related]
69. Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system.
Wu J; Zhao C; Liu Q; Huang W; Wang Y
Vaccine; 2017 Nov; 35(47):6387-6394. PubMed ID: 29031692
[TBL] [Abstract][Full Text] [Related]
70. Chikungunya virus; an emerging arbovirus in Pakistan.
Ali I; Dasti JI
J Pak Med Assoc; 2018 Feb; 68(2):252-257. PubMed ID: 29479102
[TBL] [Abstract][Full Text] [Related]
71. Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya.
Gerke C; Frantz PN; Ramsauer K; Tangy F
Expert Rev Vaccines; 2019 Apr; 18(4):393-403. PubMed ID: 30601074
[TBL] [Abstract][Full Text] [Related]
72. Fighting back against chikungunya.
Rudd PA; Mahalingam S
Lancet Infect Dis; 2015 May; 15(5):488-9. PubMed ID: 25739877
[No Abstract] [Full Text] [Related]
73. Antiviral Phosphorodiamidate Morpholino Oligomers are Protective against Chikungunya Virus Infection on Cell-based and Murine Models.
Lam S; Chen H; Chen CK; Min N; Chu JJ
Sci Rep; 2015 Jul; 5():12727. PubMed ID: 26224141
[TBL] [Abstract][Full Text] [Related]
74. Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease.
Singh H; Mudgal R; Narwal M; Kaur R; Singh VA; Malik A; Chaudhary M; Tomar S
Biochimie; 2018 Jun; 149():51-61. PubMed ID: 29635044
[TBL] [Abstract][Full Text] [Related]
75. Status of research and development of vaccines for chikungunya.
Smalley C; Erasmus JH; Chesson CB; Beasley DWC
Vaccine; 2016 Jun; 34(26):2976-2981. PubMed ID: 27026149
[TBL] [Abstract][Full Text] [Related]
76. Defining a correlate of protection for chikungunya virus vaccines.
Milligan GN; Schnierle BS; McAuley AJ; Beasley DWC
Vaccine; 2019 Nov; 37(50):7427-7436. PubMed ID: 30448337
[TBL] [Abstract][Full Text] [Related]
77. Immunogenicity of Escherichia coli expressed envelope 2 protein of Chikungunya virus.
Tripathi NK; Priya R; Shrivastava A
Bioengineered; 2014; 5(3):198-203. PubMed ID: 24637708
[TBL] [Abstract][Full Text] [Related]
78. Suramin treatment reduces chikungunya pathogenesis in mice.
Kuo SC; Wang YM; Ho YJ; Chang TY; Lai ZZ; Tsui PY; Wu TY; Lin CC
Antiviral Res; 2016 Oct; 134():89-96. PubMed ID: 27577529
[TBL] [Abstract][Full Text] [Related]
79. Antiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on Dengue and Chikungunya virus infections.
Gómez-Calderón C; Mesa-Castro C; Robledo S; Gómez S; Bolivar-Avila S; Diaz-Castillo F; Martínez-Gutierrez M
BMC Complement Altern Med; 2017 Jan; 17(1):57. PubMed ID: 28100218
[TBL] [Abstract][Full Text] [Related]
80. Cellular and Molecular Immune Response to Chikungunya Virus Infection.
Tanabe ISB; Tanabe ELL; Santos EC; Martins WV; Araújo IMTC; Cavalcante MCA; Lima ARV; Câmara NOS; Anderson L; Yunusov D; Bassi ÊJ
Front Cell Infect Microbiol; 2018; 8():345. PubMed ID: 30364124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
